Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/4/2020
SIETES contiene 92957 citas

 
 
<< anterior 21 a 40 de 41 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9. [Ref.ID 81063]
22. Cita con resumen
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, for the Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial. Ann Intern Med 2007;146:326-39. [Ref.ID 79534]
23. Cita con resumen
Anónimo. Charges hit Lilly, but profits meet forecasts. Scrip 2007;3231:13. [Ref.ID 79163]
24. Cita con resumen
Poole KES, Compston JE. Osteoporosis and its management. BMJ 2006;333:1251-6. [Ref.ID 78880]
25. Cita con resumen
Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-8. [Ref.ID 77321]
26. Cita con resumen
Kannus P, Sievänen H, Palvanen M, Järvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet 2005;366:1885-93. [Ref.ID 75522]
27. Cita con resumen
Steddon SJ, Cunningham J. Calcimimetics and calcilytics - fooling the calcium receptor. Lancet 2005;365:2237-9. [Ref.ID 74224]
28. Cita con resumen
Anónimo. Teriparatide for postmenopausal osteoporosis. Drug Ther Bull 2004;42:93-5. [Ref.ID 72233]
29. Cita con resumen
Anónimo. Tériparatide. Ostéoporose: moins bien évalué que l'acide alendronique. Prescrire 2004;24:565-9. [Ref.ID 71334]
30. Cita con resumen
Anónimo. Lilly profits hit by charges as US Zyprexa sales weaken. Scrip 2004;2973:14. [Ref.ID 70967]
31. Cita con resumen
Anónimo. After 10 years of data, Fosamax worries still longer. Scrip 2004;2971:25. [Ref.ID 70959]
32. Cita con resumen
Wharton B, Bishop N. Rickets. Lancet 2003;362:1389-400. [Ref.ID 67935]
33. Cita con resumen
Anónimo. Dr Wolfe warns against Forteo use. Scrip 2003;2838:23. [Ref.ID 65625]
34. Cita con resumen
Anónimo. Teriparatide (Forteo) for osteoporosis. Med Lett Drugs Ther 2003;45:9-10. [Ref.ID 63742]
35.Tiene citas relacionadas Cita con resumen
Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26. [Ref.ID 62291]
36.
Reid I R. Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert Opin Drug Saf 2002;1:93-107. [Ref.ID 62156]
37.
Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer R M. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34). A randomized controlled trial. JAMA 1998;280:1067-73. [Ref.ID 40443]
38.
Francis RM. Management of established osteoporosis. Br J Clin Pharmacol 1998;45:95-9. [Ref.ID 38372]
39.
Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46. [Ref.ID 37259]
40.Tiene citas relacionadas Cita con resumen
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5. [Ref.ID 35170]
Seleccionar todas
 
<< anterior 21 a 40 de 41 siguiente >>